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clinically adapted recombinant adeno-
associated virus (rAAV) vectors is an 
emerging and attractive therapeutic solu-
tion for targeted articular cartilage repair, 
allowing for a controlled and minimally 
invasive delivery of gene vectors in a spa-
tiotemporally precise manner, reducing 
intra-articular vector spread and possible 
loss of the therapeutic gene product.[4]
PEO–PPO–PEO copolymers are nonionic 
triblock copolymers based on hydrophilic 
poly(ethylene oxide) (PEO) and hydrophobic 
poly(propylene oxide) (PPO) (Figure 1a)[5] in 
a linear and bifunctional form (poloxamers) 
or X-shaped form linked by a dyamine cen-
tral core (poloxamines) (Figure 1a). These 
copolymers are self-assembling and temper-
ature sensitive, i.e., at concentrations higher 
than the critical micellar concentration 
(CMC), the individual block copolymers 
(unimers) can self-assemble into micelles. 
Likewise, by increasing temperature and 
concentration, the micelles further form 3D 
networks (gels) with high viscosity,[6] displaying a sol–gel transi-
tion around 37 °C, enabling a minimally invasive in vivo injection 
(an attractive feature for cartilage defects), and becoming semi-
solid to solid gels capable of a sustained and controlled release of 
agents at the place of implantation (Figure 1b).
These micellar systems have the ability to enhance rAAV-based 
overexpression of reporter[7,8] or chondrogenic genes such as 
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Defects of the articular cartilage, the smooth white tissue cov-
ering the ends of bones, do not regenerate and may induce 
osteoarthritis (OA),[1] the number one cause of chronic dis-
ability in the USA, afflicting more than 67 million people by 
2030[2] with total treatment costs exceeding $3 billion annu-
ally,[3] thus confronting our society with enormous problems. 
Advanced biomaterial-guided delivery of gene carriers like 
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the sex-determining region Y-type high-mobility group box 9 
transcription factor (SOX9)[9] or the transforming growth factor 
beta (TGF-β)[10] in human-bone-marrow-derived mesenchymal 
stromal cells (MSCs)[7] and in human OA chondrocytes or in 
a human osteochondral defect explant model[8–10] via effective 
rAAV-vector-controlled release.[8] Of further note, PEO–PPO–
PEO copolymer-mediated gene delivery can effectively restore 
rAAV transduction of MSCs and chondrocytes in inhibitory envi-
ronments like in the presence of AAV capsid-specific antibodies 
or of anticoagulants.[8,11] So far, to the best of our knowledge, no 
study investigated the in vivo efficacy of an injectable hydrogel 
capable of a controlled in situ release of a therapeutic rAAV 
vector to improve the repair of cartilage defects in an animal 
model in vivo. We therefore studied the effects of injecting a 
thermosensitive hydrogel based on PEO–PPO–PEO poloxamers 
for the in situ release of an rAAV encoding for the chondrogenic 
sox9 transcription factor on the repair of full-thickness chondral 
defects in a clinically relevant large animal model in vivo.
Adult Göttingen minipigs received standardized full-
thickness circular chondral defects in a standardized fashion 
(diameter = 4.0 mm) in the superior region of the lateral 
trochlear facet of both stifle joints (Figure 1c) that were each 
treated with three microfracture holes at identical distances from 
each other (awl diameter, 1.0 mm) (Figure 1d). In parallel, liquid 
PEO–PPO–PEO (PF127) hydrogels carrying either the candidate 
rAAV-FLAG-hsox9 vector (sox9/hydrogel) or a control rAAV-lacZ 
vector (lacZ/hydrogel) and showing an effective ability for rAAV 
controlled release[8] (Figure 2d) were injected into the chondral 
defects, covering the subchondral bone plate and completely 
filling the defects. In situ gelation of the PEO–PPO–PEO 
hydrogel always occurred within 2–3 min (Figure 1c). Four 
weeks postoperatively, the animals were euthanized and the 
osteochondral units containing the defects were explanted and 
subjected to standardized macroscopic, histological, immuno-
histochemical, and micro-computed tomographic (micro-CT) 
analyses to monitor early osteochondral repair.[12]
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Figure 1. Study design. a) Structure of the PEO–PPO–PEO (PF127) block copolymer. b) Thermosensitive characteristics of the copolymer (liquid form 
at 4 °C, solid form at 37 °C). c) Flowchart of generation of the rAAV/hydrogel systems for the controlled release of rAAV with implantation in knee full-
thickness chondral defects in minipigs following microfracture. The accumulated controlled release pattern of rAAV from PF127 is presented relative 
to free rAAV. d) Intraoperative view of the full-thickness chondral defect creation and treatment with microfracture augmented with in situ gelation of 
the rAAV/hydrogels. The defects were outlined in the superior region of the lateral trochlear facets of both knees with a biopsy punch and debrided 
down to subchondral bone plate after removal of the entire calcified cartilage layer. Three microfracture holes were always introduced per defect in a 
standardized manner. Then, the PEO–PPO–PEO systems carrying rAAV-FLAG-hsox9 (sox9/hydrogel) or rAAV-lacZ (lacZ/hydrogel) were directly applied 
into the treated cartilage defects, allowing for in situ gelation.
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Upon macroscopic evaluation, no joint effusion, inflammation, 
periarticular osteophyte formation, nor adhesions were observed 
in any of the treatment groups (Figure 2a). Semiquantitative 
scoring of macroscopic cartilage repair[13] (Figure 2e,f; Table S1, 
Supporting Information) revealed significantly improved total 
scores with the sox9/hydrogel (P = 0.026 vs lacZ/hydrogel, 
P = 0.018 vs lacZ) with less new blood vessels covering the repair 
tissue of defects treated with the sox9/hydrogel (P = 0.026 vs lacZ/
hydrogel, P = 0.028 vs lacZ) (Figure 2g,h; Table S1, Supporting 
Information). Other individual parameters of the macro-
scopic scoring were not significantly different between groups 
(P ≥ 0.093) (Figure 2e,f; Table S1, Supporting Information).
A histomorphometric analysis revealed that application 
of the sox9/hydrogel significantly improved the filling of 
the defects relative to all other groups (P ≤ 0.003) (Figure 2i; 
Table S2, Supporting Information) while it enhanced the thick-
ness of the cartilage versus free vector treatments (P ≤ 0.008) 
although it was significantly thinner than normal cartilage 
(P ≤ 0.001) (Figure 2j; Table S2, Supporting Information). A 
histological analysis (Figure 2b) using a semiquantitative histo-
logical scoring of cartilage repair[14] (Figure 2k) further showed 
that relative to all other groups, application of the sox9/hydrogel 
significantly improved the individual parameters of “integration” 
(P ≤ 0.025), “cellular morphology” (P = 0.001), and “matrix 
staining” (P = 0.001) (Figure 2n,p,r; Tables S3, Supporting 
Information) as well as the total histological score of cartilage 
repair (P ≤ 0.003) (Figure 2m; Table S3, Supporting Infor-
mation). The individual parameter of “surface architecture” 
was improved with the sox9/hydrogel versus lacZ/hydrogel 
(P = 0.001) while “cellularity” was enhanced versus lacZ and 
lacZ/hydrogel (P ≤ 0.022) (Figure 2o,q; Table S3, Supporting 
Information). Principal component analysis of the histological 
scoring (Figure 2l) detected a noteworthy separation among 
each dataset, indicating significant histological differences of 
cartilaginous repair tissue between groups. These data extend 
our previous in vitro findings on the effectiveness of such 
hydrogel systems as valid delivery platforms for therapeutic 
rAAV vectors in MSCs, the major cell type responsible for 
cartilage repair in this in vivo model, as already shown using 
human MSCs[7] and human articular chondrocytes.[8–10] These 
data are also in good agreement with the enhanced in vitro 
chondrogenesis of bone-marrow-derived MSCs[15] and with the 
improved repair of osteochondral defects in rabbit knee joints 
by direct, hydrogel-free sox9 gene transfer.[16]
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Figure 2. Macroscopic, histological, and immuno-histochemical analyses of cartilage repair in full-thickness chondral defects in minipigs upon 
microfracture and application of sox9/hydrogel versus lacZ/hydrogel and free vector treatment 4 weeks postoperatively. a) Macroscopic views 
(all representative data). b) Histological views showing better repair with larger chondrogenic foci (*) in the sox9/hydrogel defects (all representative 
data). White triangles denote the defect borders. c) Immunodetection of type-II collagen deposition (all representative data). d) Immunodetection of 
SOX9 expression (all representative data). e) Heat map of variables of the macroscopic scoring with (*) indicating significant intergroup difference 
for blood vessels coverage. f) Principal component analysis of total macroscopic score underlining the overlapped clusters without clear separations. 
g) Macroscopic total score. h) Macroscopic blood vessel coverage. i) Defect filling (%). j) Cartilage thickness (µm). k) Heat map of variables of the 
histological scoring. Variables with significant intergroup differences are shown by (*). l) Principal component analysis of total histological score high-
lighting the evidently separated clusters of the sox9/hydrogel group from all other groups and the overlapping seen between free sox9 and lacZ groups. 
m) Histological total score. n) Histological integration score. o) Histological surface architecture. p) Histological cellular morphology. q) Histological 
cellularity. r) Histological matrix staining. s) Type-II collagen-positive cells. t) SOX9-positive cells. Scale bars: a) 2.0 mm, b,c) 0.5 mm, and d) 1.0 mm.
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Figure 3. Quantitative analyses of collagen fiber orientation of the repair tissue within the articular cartilage zone. a) Representative polarized micro-
scopic views of normal cartilage and defects from both treatment groups. b) Vector filed illustration. c) Region of interests (ROIs) within the articular 
cartilage zone: surface ROI with one-third total thickness and base ROI with two-thirds total thickness. d) Collagen orientation within the surface ROI. 
e) Collagen orientation within the base ROI. *P ≤ 0.05 for comparison between normal cartilage and lacZ/hydrogel defects; δP ≤ 0.05 for comparison 
between normal cartilage and sox9/hydrogel defects; #P ≤ 0.05 for comparison between both groups. f,g) Radar charts of collagen orientation within 
both surface (f) and base (g) ROIs.
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We also observed higher type-II collagen deposition in the 
sox9/hydrogel defects compared with the lacZ/hydrogel group 
or with free lacZ application (P ≤ 0.026) (Figure 2c,s; Table S4, 
Supporting Information), probably resulting from higher num-
bers of SOX9-positive cells in the sox9/hydrogel defects relative 
to all other groups (P ≤ 0.001) (Figure 2d,t; Table S4, Supporting 
Information), indicating improved transgene expression via 
PEO–PPO–PEO-guided rAAV controlled release.
An immuno-histochemical analysis on histological sections 
to detect potential CD3 (T-lymphocytes), CD11b (activated mac-
rophages), and human leukocyte antigen isotype DR alpha 
(HLA-DRα) (class II major histocompatibility complex (MHC) 
antigens) expression[17] revealed the quasiabsence of immune 
cells in all the defects without significant differences between 
groups (P ≥ 0.220) (Figure S1 and Table S5, Supporting Infor-
mation). The absence of immune response in the current 
design, even after long time body exposure to the vectors, is 
in good agreement with our previous findings in vivo using 
rAAV vectors in a free form[16] and with the observation that 
PEO–PPO–PEO poloxamers can protect rAAV-mediated gene 
transfer from neutralization by antibodies directed against the 
AAV capsid in vitro and in experimental cartilage defects.[8,11] 
Overall, these observations further confirm the benefits of 
applying this class of gene vehicles for clinical purposes com-
pared with the effective but highly immunogenic and transient 
adenoviral vectors.[18]
As such evaluations overall demonstrated superior cartilage 
repair via hydrogel-guided rAAV delivery over free rAAV vector 
treatment, we next focused on in-depth microstructural, com-
parative analyses in the sox9/hydrogel versus lacZ/hydrogel 
groups. An evaluation of collagen orientation and distribution 
detected visually better and more collagens distributed in posi-
tive degree toward the subchondral bone plate in the basal zone 
of the sox9/hydrogel defects than in the lacZ/hydrogel defects 
(Figure S2, Supporting Information). Further analyses revealed 
differences between groups in two subregions of interest (ROIs) 
of the cartilaginous repair tissue (Figure 3a–c). Compared with 
the surface zone of normal cartilage, significant less collagens 
oriented between −10° and 0° and between 80° and 90° were 
observed in either group compared with normal cartilage 
(Figure 3d,f). Within the basal zone of the cartilaginous repair 
tissue, collagen orientation in the lacZ/hydrogel defects showed 
significant different patterns in multiple degree ranges (from 
−90° to −80°, −60° to −50°, 20° to 30°, 40° to 50°, and 80° to 
90°; all P ≤ 0.05) compared with normal cartilage, while the 
sox9/hydrogel defects showed orientation and distribution of 
collagens more analogous to normal cartilage (Figure 3e,g). 
These findings suggest that sox9/hydrogel delivery yielded 
a better approximation of the normal zonal collagen net-
work than the control condition, especially in the basal zone. 
Mimicking the primary vertical orientation in the base zone 
of the normal cartilage, these restored collagen fibrils by sox9 
treatment may significantly increase the stiffness of the tissue 
and protect the solid matrix against large distortions and strains 
at the subchondral junction,[19] possibly yielding a persistent 
and enhanced cartilaginous repair tissue.
We next performed histomorphometric analyses to deter-
mine the effects of the rAAV/hydrogels on chondrogen-
esis and osteogenesis within the osteochondral unit in vivo 
(Figure 4a,b). Compared with the lacZ/hydrogel defects, the 
sox9/hydrogel defects exhibited a significantly larger area 
of mature chondrogenic foci (P = 0.046) with a significantly 
improved area of chondrogenic foci/soft repair tissue ratio 
(P = 0.046) (Figure 4c; Table S6, Supporting Information). 
Moreover, significantly more chondrocytes, less MSCs, and 
higher cellularity ratio of chondrocytes versus MSCs were 
observed in the osteochondral repair tissue of the sox9/hydrogel 
defects compared with the control defects (P = 0.002). 
Taken together, these data indicate that sox9 treatment via 
PEO–PPO–PEO hydrogel-guided delivery significantly improved 
major parameters of a stratified zonal in situ chondrogenesis.[20]
As microfracture also exerts effects on the subchondral 
bone,[21] we also searched for possible subchondral bone 
changes in the defects (Figure S3, Supporting Information). 
Histomorphometric analyses evidence newly formed bone 
always located at the margin of the soft repair tissue. Applica-
tion of the sox9/hydrogel led to a significantly higher total oste-
oclast (P = 0.004) and osteoblast (P = 0.002) density in the repair 
tissue and marrow cavity than the control group (Figure 4d,e). 
2D bony structure parameters (bone volume fraction, BV/TV; 
trabecular thickness, Tb.Th; trabecular separation, and Tb.Sp; 
trabecular number, Tb.N) and measurements of structural 
components (marrow cavity, mature and new bone, and repair 
tissue) were not significantly different (P ≥ 0.05) (Figure 4f,g; 
Table S7, Supporting Information).
Applying a micro-CT-based algorithm,[22] residual micro-
fracture holes, perihole bone resorption, and intralesional 
osteophytes (lacZ/hydrogel: n = 2; sox9/hydrogel: n = 1) were 
identified in both groups without significant differences 
(P ≥ 0.05) (Figure S3, Supporting Information). An analysis 
of all 18 microfracture holes per group showed no significant 
differences in the perihole bone resorption and bone bridge 
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Figure 4. Histomorphometric analyses of chondrogenesis and osteogenesis in the osteochondral unit. a) Illustration of the regions of interest (ROIs). 
ROIs of osteochondral unit include both articular cartilage (ROI-cartilage; black dashed rectangle) and subchondral bone (ROI-bone; yellow dashed 
rectangle). Quantification of chondrogenic foci was performed within both ROI-cartilage and ROI-bone, while quantification of chondrocytes and bone-
marrow-derived MSCs was achieved within the center of the osteochondral unit within up to three additional defined ROIs (roi1-3; black rectangles), 
depending on the depth of the soft osteochondral repair tissue. b) Representative chondrogenic foci (white *) with chondrocytes (black arrows) and 
MSCs (white arrows). Note the more mature and larger chondrogenic foci in the sox9/hydrogel defects than in the lacZ/hydrogel defects. c) Significantly 
larger area of chondrogenic foci and area ratio of chondrogenic foci to soft repair tissue with considerably more chondrocytes, less MSCs, and higher 
cellularity ratio of chondrocytes to MSCs in the osteochondral repair tissue in the sox9/hydrogel defects than the lacZ/hydrogel defects. The numbers of 
chondrogenic foci and area of soft repair tissue are comparable between both groups. d) Bone histomorphometry within ROI-bone. Note the interfer-
ence of newly formed bone (NB) within the mature bone (MB) at the margin of soft repair tissue and osteoblasts (white arrowheads) and osteoclasts 
(black arrowheads) within the repair tissue and marrow cavity. e) Significantly higher total osteoclast and osteoblast density within the repair tissue 
of the sox9/hydrogel defects than the lacZ/hydrogel defects. f) No differences in BV/TV, TB.Th, Tb.Sp, and Tb.N between both groups. g) Percentage 
of areas occupied by marrow cavity (white), mature bone (light red), new bone (red), and soft repair tissue (green) within ROI-bone of both groups.
www.advmat.dewww.advancedsciencenews.com
1906508 (7 of 8) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
height between groups (P ≥ 0.05) (Tables S8 and S9, Sup-
porting Information). Microstructural evaluation of the entire 
region below the cartilage defect revealed a considerable early 
affection of the subchondral bone plate in both groups, with 
decreased BV/TV, specific bone surface (BS/BV), bone surface 
density (BS/TV), and cortical thickness (Ct.Th) compared with 
the normal osteochondral unit (Figure S4, Supporting Infor-
mation). Such early loss of the subchondral bone induced by 
microfracture suggests that stimulation of new bone formation 
underlying the treated defects possibly occurs at later time 
points[23] and, from a clinical perspective, highlights the impor-
tance of a protected weight bearing within the first 6 weeks 
postoperatively when performing marrow stimulation in the 
tibiofemoral compartment.[24] Of special importance, sox9/
hydrogel treatment led to a significantly higher BV/TV of the 
subchondral bone plate than the control treatment (P = 0.002), 
suggesting a preserving effect of the sox9/hydrogel on the 
subchondral bone plate. The subarticular spongiosa was less 
affected by such changes, as no differences of BV/TV, BS/BV, 
and Tb.Th were found between the normal osteochondral unit 
and defects treated by either the lacZ/hydrogel or the sox9/
hydrogel (P ≥ 0.05). Treatment with the lacZ/hydrogel yielded 
significantly less BS/TV than the normal osteochondral unit 
(P = 0.002) (Table S10, Supporting Information).
This study holds some limitations. First, the 4 week time 
point selected for assessment of early osteochondral repair does 
not allow for a final assessment of the long-term effectiveness. 
Second, the full postoperative weight bearing as requested by 
animal welfare is not comparable to a clinical rehabilitation. 
The strengths of the study include the use of a translational 
animal model at an early time point, allowing for an in-depth 
analysis of the very early outcomes of marrow stimulation, and 
the comprehensive analyses of the entire osteochondral unit 
based on a variety of robust evaluation methods using categor-
ical and continuous data.
Taken together, the present study shows, for the first time 
to our best knowledge, that a thermosensitive hydrogel based 
on PEO–PPO–PEO poloxamers controlling the release of 
a therapeutic (sox9) rAAV vector significantly improves the 
repair of full-thickness chondral defects in a clinically relevant 
large animal model in vivo. These copolymers are highly 
promising materials for in vivo rAAV delivery, supporting car-
tilage repair in conditions where protection against potentially 
damaging host immune responses may need to be afforded. 
The data support the concept of advanced biomaterial-guided 
delivery of gene carriers as an attractive therapeutic option for 
cartilage repair, enabling for a controlled and minimally inva-
sive delivery[25] of genes without loss of the therapeutic gene 
product in vivo. From a clinical translational point of view, such 
biomaterial-guided gene vector delivery is particularly attractive 
for cartilage defects that are arthroscopically treated with micro-
fracture and may represent a major step toward improved carti-
lage repair in the near future.
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